Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rubicon Filter

This article was originally published in The Gray Sheet

Executive Summary

Embolic protection device indication for use in saphenous vein grafts will be sought using data from a conventional, single-device U.S. study, expected to begin early in 2005, Rubicon Medical says. Initial plans for a joint, randomized RULE-SVG trial with Boston Scientific's Taxus Liberté paclitaxel-eluting stent have been scrapped to ensure "fewer delays and complexities" following FDA feedback, the firm explains (1"The Gray Sheet" Aug. 23, 2004, In Brief). Separately, Rubicon has finalized a license for SurModics' hydrophilic coating to enhance filter deliverability...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT021356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel